- RVL Pharmaceuticals (NASDAQ:RVLP) rose 7.7% pre market after it notifies preliminary fourth quarter and full year 2022 net product sales of UPNEEQ of ~$12.1M and $36.5M, respectively.
- The preliminary fourth quarter 2022 net product sales of UPNEEQ represent a sequential increase of 21% from the third quarter 2022.
- The company also announced that ~4,300 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the fourth quarter 2022, a 23% increase from the end of the third quarter 2022.